What's happening
This bill prohibits price gouging of medicines during FDA-reported shortages by imposing penalties on sellers who charge excessively high prices.
Why it matters
Targets unfair price hikes only during official shortages. The bill applies specifically to medicines listed as in shortage by the FDA, meaning it focuses on critical periods when patients are most vulnerable to sudden price increases, rather than generally regulating drug prices.
Broad accountability across the supply chain. All parties involved in selling the drug—manufacturers, wholesalers, distributors, and retailers—are covered, ensuring that no link in the supply chain can exploit shortages for excessive profits.
Defines and adjudicates “unconscionably excessive” pricing. Courts must consider both the size of the price hike and any evidence of unfair leverage or means. Sellers can defend themselves by showing their costs increased or their profit margin has not changed, providing some protection for legitimate business responses to shortages.
Imposes significant penalties and restitution. Violators face steep civil penalties—up to $25,000 per violation, or three times the gross receipts from the drug, whichever is higher—and courts may order them to compensate those harmed, creating a strong financial deterrent to price gouging.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Stop Medicine Price Gouging
Plain English, a few words. Used as the page title.
Sponsors
History
- Vetoed memo.162
- Delivered to governor
- Returned to senate
- Passed assembly
- Ordered to third reading rules cal.528
- Substituted for A5860B
- Referred to codes
- Returned to assembly
- Repassed senate
- Amended on third reading 3081b
- Vote reconsidered - restored to third reading
- Returned to senate
Show 17 earlier actions
- Recalled from assembly
- Referred to consumer affairs and protection
- Delivered to assembly
- Passed senateVote 61–0
- Amended on third reading 3081a
- Advanced to third reading
- 2nd report cal.
- 1st report cal.461
- Referred to consumer protection
- Returned to senate
- Died in assembly
- Referred to consumer affairs and protection
- Delivered to assembly
- Passed senateVote 63–0
- Ordered to third reading cal.1528
- Committee discharged and committed to rules
- Referred to consumer protection
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Stop Medicine Price Gouging
Assembly Floor Calendar · Sponsor Karines Reyes
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
3081--B Cal. No. 461
2021-2022 Regular Sessions
IN SENATE
January 27, 2021
Introduced by Sens. SALAZAR, BIAGGI, BRISPORT, GIANARIS, JACKSON, KRUEG- ER, LANZA, REICHLIN-MELNICK, SANDERS -- read twice and ordered printed, and when printed to be committed to the Committee on Consumer Protection -- recommitted to the Committee on… Show allHide
Introduced by Sens. SALAZAR, BIAGGI, BRISPORT, GIANARIS, JACKSON, KRUEG- ER, LANZA, REICHLIN-MELNICK, SANDERS -- read twice and ordered printed, and when printed to be committed to the Committee on Consumer Protection -- recommitted to the Committee on Consumer Protection in accordance with Senate Rule 6, sec. 8 -- reported favorably from said committee, ordered to first and second report, ordered to a third reading, amended and ordered reprinted, retaining its place in the order of third reading -- passed by Senate and delivered to the Assembly, recalled, vote reconsidered, restored to third reading, amended and ordered reprinted, retaining its place in the order of third reading
AN ACT to amend the general business law, in relation to the price gouging of medicine
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The general business law is amended by adding a new section 396-rrr to read as follows:
§ 396-rrr. Price gouging of medicine. 1. For the purposes of this section, "drug subject to a shortage" shall mean any drug or medical product intended for human use publicly reported as being subject to a shortage by the U.S. food and drug administration on its website, provided, however, that a drug or medical product shall only be considered a "drug subject to a shortage" during the period of time that such drug or medical product is listed as being subject to a shortage on such website.
2. No manufacturer, supplier, wholesaler, distributor or retail seller of any drug subject to a shortage shall sell or offer to sell any such drug subject to a shortage for an amount which represents an unconscionably excessive price.
3. Whether a price is unconscionably excessive is a question of law for the court.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD06581-05-2
(a) The court's determination that a violation of this section has occurred shall be based on any of the following factors:
(i) that the amount of the excess in price is unconscionably extreme;
(ii) that there was an exercise of unfair leverage or unconscionable means; or
(iii) a combination of both factors in subparagraphs (i) and (ii) of this paragraph.
(b) In any proceeding commenced pursuant to subdivision four of this section, prima facie proof that a violation of this section has occurred shall include evidence that:
(i) the amount charged represents a gross disparity between the price of the drug subject to a shortage which was the subject of the transaction and their value measured by the price at which such drug was sold or offered for sale by the defendant in the usual course of business immediately prior to the onset of the shortage; or
(ii) the amount charged grossly exceeded the price at which the same or similar drug subject to a shortage was readily obtainable by other purchasers in the trade area.
(c) A defendant may rebut a prima facie case with evidence that:
(i) the increase in the amount charged preserves the margin of profit that the defendant received for the same drug subject to a shortage prior to the onset of the shortage; or
(ii) additional costs not within the control of the defendant were imposed on the defendant for the drug subject to a shortage.
4. Where a violation of this section is alleged to have occurred, the attorney general may apply in the name of the People of the State of New York to the supreme court within the judicial district in which such violation is alleged to have occurred, on notice of five days, for an order enjoining or restraining commission or continuance of the alleged unlawful acts. In any such proceeding, the court shall impose a civil penalty in an amount not to exceed twenty-five thousand dollars per violation or three times the gross receipts for the relevant drug subject to the shortage, whichever is greater, and where appropriate, order restitution to aggrieved parties.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the general business law, in relation to the price goug- ing of medicine
Purpose or general idea of the bill
This legislation adds medicine to the list of goods and services that can be classified as possibly being subject to price gouging.
Summary of specific provisions
Section 1: Section 396-rrr of the general business law is amended to add medicine to the list of consumer goods that can be classified as subject to price gouging. The classification of medicines falling under this section of law will be determined by the publicly reported drug short- ages reported by the U.S. Food and Drug Administration (FDA).
Read the full memo (694 words)
Section 2: Bans the price gouging of medicines listed as been in short supply by the U.S. FDA.
Section 3: Allows for the courts to determine if the price established for a drug in short supply is unconscionably excessive and establishes the criteria for the court to consider such determination.
Section 4: Extends medicine price gouging prosecution powers to the Attorney General of New York State.
Justification
After workshops on improving health care access for Latinos by the NYS Assembly Puerto Rican Hispanic Task Force (PRHTF) during its annual legislative conference and after data reported by the Associated Press (AP) on the price gouging of medicines on short supply was made public on September 23, 2011, legislation to ban the practice was introduced by the PRHTF. The AP report documents that there was an ongoing and "severe shortage of drugs for chemotherapy, infections and other serious ailments which is endangering patients and forcing hospitals to buy life-saving medications from secondary suppliers at huge markups because they can't get them any other way."
An Associated Press review of industry reports and interviews with near- ly two dozen experts found at least 15 deaths in the past 15 months due to the shortages, (i.e. the correct drug wasn't available, dosing errors, problems in administering or preparing alternative medications).
Despite this, many deaths still go unreported. The shortages, mainly involving widely used generic injected drugs that ordinarily are inex- pensive, have been delaying surgeries and cancer treatments, leaving patients in unnecessary pain and forcing hospitals to give less effec- tive treatments. This results in complications and longer hospital stays.
Over half of 549 U.S. hospital responses to a survey by the Institute for Safe Medication Practices, said they had purchased one or more prescription drugs from so-called "gray market vendors" - secondary market companies that purchase scare drugs from small regional whole- salers, pharmacies, or others sources and then gouge the prices of the products when selling them to hospitals. Most hospitals also said they've had to do so more often of late, and 7 percent reported side effects or other problems.
The average price markup on drugs sold by secondary distributors were 650 percent. In an extreme case, one vendor was offering a generic drug for high blood pressure, normally priced at $25.90 per dose, for $1,200.
Social justice impact
This legislation would contribute to the right of New Yorkers to afford- able and exceptional health care. This legislation would put the afford- able treatment of New Yorkers over the profits of secondary market companies.
Amended version
The "B" Print clarified an error that appeared in the "A" Print. The difference between the "B" Print and the original bill are a clarifica- tion of the wording in Section 2, elimination of the private right of action, and reduction of potential penalty for a violation.
Prior legislative history
SENATE
S.3654 of 2019
02/11/19 REFERRED TO CONSUMER PROTECTION
06/12/19 COMMITTEE DISCHARGED AND COMMITTED TO RULES
06/12/19 ORDERED TO THIRD READING CAL. 1299
06/12/19 PASSED SENATE
06/12/19 DELIVERED TO ASSEMBLY
06/12/19 referred to consumer affairs and protection
01/08/20 died in assembly
01/08/20 returned to senate
01/08/20 REFERRED TO CONSUMER PROTECTION
02/12/20 1ST REPORT CAL.437
02/13/20 2ND REPORT CAL.
02/24/20 ADVANCED TO THIRD READING
02/25/20 PASSED SENATE
02/25/20 DELIVERED TO ASSEMBLY
02/25/20 referred to consumer affairs and protection
A8801 of 2012
Passed Assembly 2012-2018. Died in Senate 2012-2018.
Fiscal implications for state and local government
None
Effective date
This bill will take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.